ALB and non-Hodgkin lymphoma: A European prospective observational study based on patients with non-Hodgkin’s lymphoma (NHL) presented a risk model for the development of FN in the first cycle of chemotherapy, clinical correlates significantly associated with FN in cycle 1 were: older age, planned dose increase of cyclophosphamide, history of prior chemotherapy, recent history of infection, low baseline albumin level [18].